Abstracts tagged "Biosimilars and etanercept"

Abstract Number: 2511 • 2018 ACR/ARHP Annual Meeting
Benepali Switches in Clinical Practice – a Positive Single Centre Experience
Hoda Alkoky, Angela Pakozdi and Hasan Tahir, Rheumatology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Benepali (SB4) an etanercept (ETN) biosimilar, has demonstrated comparable efficacy in randomised controlled trials. Switching patients to biosimilars has cost benefits to the national…
Abstract Number: 2533 • 2018 ACR/ARHP Annual Meeting
Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study
Anastasia- Vasiliki Madenidou¹, Andrew Jeffries², Sneha Varughese², Stephen Jones², Helen Veevers², Hanadi Sari- Kouzel² and Chandini Rao², ¹Rheumatology, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom, ²Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel.In 2016, the Rheumatology Department at Blackpool…
Abstract Number: 2550 • 2018 ACR/ARHP Annual Meeting
Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
Arthur Kavanaugh¹, Marco Matucci-Cerinic², Hendrik Schulze-Koops³, Maya Buch⁴, Yannick Allanore⁵, Eugeniusz J. Kucharz⁶ and Goran Babic⁷, ¹UC San Diego School of Medicine, La Jolla, California, La Jolla, CA, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Ludwig-Maximilians-University, Munich, Germany, Munich, Germany, ⁴University of Leeds, United Kingdom, Leeds, United Kingdom, ⁵Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ⁶Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland, Katowice, Poland, ⁷Hexal AG, a Sandoz company, Holzkirchen, Germany, Holzkirchen, Germany
Background/Purpose: Compared to ETN, GP2015 has equivalent efficacy, and comparable safety and immunogenicity in patients with chronic plaque-type psoriasis.1 The purpose of this study is…
Abstract Number: 1470 • 2017 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody and Injection Site Reaction on Efficacy: 24-Week Results from a Phase III Study Comparing SB4 (etanercept biosimilar) with Reference Etanercept in Patients with Rheumatoid Arthritis
Jiri Vencovsky¹, Paul Emery², Edward C. Keystone³, Jeehoon Ghil⁴, Soo Yeon Cheong⁴ and Evelyn Hong⁴, ¹Institute of Rheumatology, Deartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Toronto, Toronto, ON, Canada, ⁴Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose : SB4 is approved by the European Commission as a biosimilar of the reference etanercept (ETN). The phase III clinical study results have been…
Abstract Number: 2467 • 2017 ACR/ARHP Annual Meeting
Evaluation of Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB4 or Reference Etanercept: Results from a Phase III Study
Paul Emery¹, Jiri Vencovsky², Jeehoon Ghil³, Soo Yeon Cheong³ and Evelyn Hong³, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Institute of Rheumatology, Deartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose : SB4 has been approved as a biosimilar of the reference etanercept by the European Commission. Results including one year radiographic progression from the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].